Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 11, 2024
Event: Execution of an Amended and Restated Employment Agreement with Kyle Gano, Ph.D., in connection with his appointment as President and Chief Executive Officer, effective October 11, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Compensation Details
The filing details the new compensation structure for Dr. Gano, effective October 11, 2024:
- Base Salary: $900,000 annually.
- Cash Incentive Bonus: Target amount equal to 100% of base pay.
- Equity Grants (Target Values):
- Stock Options: Approximately $750,000 (vesting monthly over 4 years).
- Restricted Stock Units (RSUs): Approximately $300,000 (vesting annually over 4 years).
- Performance-Vesting RSUs (PRSUs): Approximately $450,000 (vesting per March 2024 executive terms).
- Grant Timing: Equity grants will be issued two business days after the filing of the first Form 10-Q following the effective date, contingent on continued employment.
Severance and Change in Control Provisions
The agreement outlines specific severance benefits upon "involuntary termination" (without cause or resignation for good reason), subject to a release of claims:
- Outside Change in Control Period:
- Cash severance: 1.5x (Base Salary + Target Bonus).
- Pro rata bonus based on actual performance.
- Health coverage: Up to 18 months.
- Equity: Accelerated vesting of time-based awards for 15 months; performance awards vest based on Compensation Committee discretion.
- Within Change in Control Period:
- Cash severance: 2.0x (Base Salary + Target Bonus).
- Pro rata bonus based on target performance.
- Health coverage: Up to 24 months.
- Equity: Full acceleration of all awards; performance awards vest at the greater of target or actual performance.
- Death or Disability: Full acceleration of all equity awards (performance awards at greater of target or actual).
Investor Verification Checklist
- Verify the exact number of shares underlying the equity grants once the grant date is determined (dependent on stock price at that time).
- Review the full text of the Employment Agreement (to be filed as an exhibit) for specific definitions of "cause," "good reason," and "change in control."
- Monitor the upcoming Form 10-Q filing to confirm the issuance of the Promotion Equity Grants.
- Assess the impact of the new CEO's compensation structure on future stock-based expense dilution.